Rare Neoplasm

Observed

← altered in cohorts of

MAP2K1

113 / 1,270 cases (8.9 %) · ssm · hdcn_msk_2025

—

Observed

← altered in cohorts of

DNMT3A

104 / 1,270 cases (8.2 %) · ssm · hdcn_msk_2025

—

Observed

← altered in cohorts of

KRAS

102 / 1,270 cases (8.0 %) · ssm · hdcn_msk_2025

—

Observed

← altered in cohorts of

TET2

66 / 1,270 cases (5.2 %) · ssm · hdcn_msk_2025

—

Observed

Rare Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived123 of 123show fewer
→ investigated in trials for	Fludarabinesmall molecule 18 trials (6 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 16 trials (9 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Tagraxofuspother 8 trials (5 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Vemurafenibsmall molecule 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Avapritinibsmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenibsmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Palbociclibsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinibsmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Masitinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Azacitidinesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cobimetinibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Midostaurinsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Selinexorsmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Tazemetostatsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Thiotepasmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Alectinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenib/Trametinib Regimen 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Dasatinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Decitabinesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Ensartinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Erdafitinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Glofitamabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinib Mesylatesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Ivosidenibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Larotrectinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pazopanibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pyrotinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Samotolisibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Selpercatinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sintilimabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenib Tosylatesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Temsirolimussmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Tipifarnibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adebrelimabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Afatinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Akt Inhibitor MK2206 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Alemtuzumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Aumolertinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Axicabtagene Ciloleucelgene therapy 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Binimetinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Brentuximab Vedotinadc 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Camrelizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cemiplimabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Clofarabinesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Crizotinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Dactinomycinother 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Denosumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Entrectinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Epirubicinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	FOLFIRI Regimen 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Gefitinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Hydroxychloroquinesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibuprofensmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ifosfamidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Immunotherapy 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Mercaptopurinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Mirdametinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nilotinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	O6-Benzylguaninesmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Osimertinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Panitumumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pirtobrutinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Polatuzumab Vedotinadc 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ripretinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Romidepsinother 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ruxolitinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Savolitinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Selumetinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Serplulimabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Sirolimussmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Tovorafenibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Tremelimumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Valproic Acidsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Vinorelbinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Zolbetuximabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →

Rare Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived123 of 123show fewer

→ investigated in trials for

Fludarabinesmall molecule

18 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

16 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tagraxofuspother

8 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vemurafenibsmall molecule

7 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avapritinibsmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dabrafenibsmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rituximabmonoclonal antibody

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Palbociclibsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trametinibsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Venetoclaxsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinibsmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Masitinibsmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Azacitidinesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cobimetinibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Midostaurinsmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selinexorsmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tazemetostatsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Thiotepasmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alectinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cytarabinesmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

Dabrafenib/Trametinib Regimen

→ investigated in trials for

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dasatinibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Decitabinesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ensartinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erdafitinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Glofitamabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinib Mesylatesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ivosidenibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Larotrectinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pyrotinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Samotolisibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selpercatinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sintilimabmonoclonal antibody

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tipifarnibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adebrelimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Akt Inhibitor MK2206

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alemtuzumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aumolertinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Axicabtagene Ciloleucelgene therapy

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Binimetinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Brentuximab Vedotinadc

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Camrelizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cemiplimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Clofarabinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Crizotinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dactinomycinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Denosumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Entrectinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Epirubicinsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

FOLFIRI Regimen

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gefitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Hydroxychloroquinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ibrutinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ibuprofensmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Immunotherapy

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mercaptopurinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mirdametinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nilotinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

O6-Benzylguaninesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Obinutuzumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Osimertinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Panitumumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pirtobrutinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Polatuzumab Vedotinadc

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ripretinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Romidepsinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ruxolitinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Savolitinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Selumetinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Serplulimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sirolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tovorafenibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trastuzumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Valproic Acidsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinorelbinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Zolbetuximabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Rare Neoplasm studied in …STUDIED_INderived10 of 360show all (up to 200)
→ studied in	NCT07489378recruiting NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors · condition mapped ALIAS · 360 trials mapped (167 active)	—	—	Rare Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03779854Phase 2 · active not recruiting Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)	—	—	Blastic Plasmacytoid Dendritic Cell Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04044859Phase 1 · active not recruiting ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) · condition mapped ALIAS · 360 trials mapped (167 active)	—	—	Childhood Gastric Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04910685Phase 2/Phase 3 · recruiting (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT02792582Phase 2 · active not recruiting A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)	—	—	Craniopharyngioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03210714Phase 2 · active not recruiting Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 360 trials mapped (167 active)	—	—	Langerhans Cell Histiocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07835165NA · not yet recruiting A Comparative Study Evaluating the Impact of Intensive Dietary Care on Weight Change and Biological Parameters in Patients Who Underwent Surgery for Craniopharyngioma During the First Postoperative Year · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)	—	—	Craniopharyngioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03698994Phase 2 · active not recruiting Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 360 trials mapped (167 active)	—	—	Histiocytic and Dendritic Cell Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00044122recruiting Study of Factors Regulating Mast Cell Proliferation · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)	—	—	Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT05786924Phase 1/Phase 2 · recruiting Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies · condition mapped ALIAS · 360 trials mapped (167 active)	—	—	Histiocytic and Dendritic Cell Neoplasm	1	Observed	clinicaltrials	graph →

Rare Neoplasm studied in …STUDIED_INderived10 of 360show all (up to 200)

→ studied in

NCT07489378recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors · condition mapped ALIAS · 360 trials mapped (167 active)

—

Observed

Blastic Plasmacytoid Dendritic Cell Neoplasm

→ studied in

NCT03779854Phase 2 · active not recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)

—

Observed

Childhood Gastric Carcinoma

→ studied in

NCT04044859Phase 1 · active not recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) · condition mapped ALIAS · 360 trials mapped (167 active)

—

Observed

Indolent Systemic Mastocytosis

→ studied in

NCT04910685Phase 2/Phase 3 · recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)

—

Observed

→ studied in

NCT02792582Phase 2 · active not recruiting

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)

—

Craniopharyngioma

Observed

Langerhans Cell Histiocytosis

→ studied in

NCT03210714Phase 2 · active not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 360 trials mapped (167 active)

—

Observed

→ studied in

NCT07835165NA · not yet recruiting

A Comparative Study Evaluating the Impact of Intensive Dietary Care on Weight Change and Biological Parameters in Patients Who Underwent Surgery for Craniopharyngioma During the First Postoperative Year · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)

—

Craniopharyngioma

Observed

→ studied in

NCT03698994Phase 2 · active not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) · condition mapped CURATED_BROADER · 360 trials mapped (167 active)

—

Observed

→ studied in

NCT00044122recruiting

Study of Factors Regulating Mast Cell Proliferation · condition mapped ONTOLOGY_EXACT · 360 trials mapped (167 active)

—

Mastocytosis

Observed